Why Are Evaxion Biotech Shares Trading Higher Today

Vandana Singh
1 min read
0
In this article:

  • Evaxion Biotech A/S (NASDAQ: EVAX) presented clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting.

  • The Phase 1 trial successfully met primary endpoints for the safety and tolerability of EVX-01 in metastatic melanoma patients and demonstrated positive clinical responses in 8 out of 12 (67%) treated patients.

  • Also Read: Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients.

  • In addition, Evaxion's proprietary AI technology PIONEER was able to identify high-quality cancer vaccine targets, so-called neoantigens, associated with longer progression-free survival.

  • The study demonstrated the ability of the PIONEER platform to identify vaccine targets associated with improved patient outcomes.

  • Stratification based on PIONEER scores outperformed tumor mutational burden as a predictive biomarker, with patients having high-quality neoantigens showing better treatment responses and longer progression-free survival.

  • The evaluation of treatment-related immune responses revealed strong neoantigen T-cell responses in all 12 patients, mediated by activated CD4+ T cells in all cases and CD8+ T cells in 7 out of 12 patients.

  • Further, immune response magnitude correlated with the vaccination dose.

  • Price Action: EVAX shares are up 10.80% at $1.64 on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Why Are Evaxion Biotech Shares Trading Higher Today originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories